# **Describing the Epidemiology of Microvascular Complications of Diabetes in a Primary Care Patient Population in Canada**

Pathiraja D.H.<sup>1</sup>, Black J.<sup>2,3</sup>, Senior P.A.<sup>4</sup>, Kim J.W.<sup>1</sup>, Williamson T.<sup>2,3</sup>, Butalia S.<sup>2,5</sup>, McBrien K.<sup>1,2</sup>, Cummings M.<sup>2,3</sup>, Drummond N.<sup>1,6</sup> 1. Dept. of Family Medicine, University of Calgary 2. Dept. of Community Health Sciences, University of Calgary 3. Centre for Health Informatics, University of Calgary 4. Alberta Diabetes Institute, Li Ka Shing Center for Health Innovation, Edmonton 5. Division of Endocrinology, Dept. of Medicine, University of Calgary 6. Dept. of Family Medicine, University of Alberta



# **Background & Objective**

Diabetes (DM) & related complications are commonly managed in primary care settings<sup>1,2</sup>

There is limited information about the prevalence & epidemiology of diabetes complications in primary care

#### Approach

**Data Source & Setting:** Diabetes Action Canada National Diabetes Repository (DAC-NDR) with electronic medical records of patients of participating primary care providers in AB, MB, ON, QC & NL

**Study Population:** Adults (18+) diagnosed with DM who

### Conclusions

The prevalence of diabetes complications was high in this primary care population of people living with diabetes

Having one or more comorbidities significantly increased the prevalence of being diagnosed with a diabetes complication

Neuropathy, retinopathy & nephropathy are common microvascular complications of diabetes<sup>3-6</sup>

This study **aims** to better understand the epidemiology of microvascular diabetes complications in people visiting primary care clinics across Canada

# Results

Study Population Characteristics	Complication(s) n=26,876 (35.4)	No Complications n=48,960 (64.6)
Sex: female, n(%)	12,972 (48.3)	23,323 (47.6)
Age, n(%)		
18-44	923 (3.4)	5,677 (11.6)
45-74	13,768 (51.2)	34,492 (70.4)
75+	12,185 (45.3)	8,791 (18.0)
Location: rural, n(%)	3,963 (14.7)	7,615 (15.6)
Comorbidities <sup>a</sup> , n(%)		
0	871 (3.2)	4,600 (9.4)
1-2	8,961 (33.3)	24,454 (49.9)
3+	17,044 (63.4)	19,906 (40.7)
HbA1C, n(%)		
≤ 6	3,638 (13.5)	7,708 (15.7)
7-9	20,240 (75.3)	34,696 (70.9)
> 9	2,789 (10.4)	4,408 (4.4)
eGFR <i>,</i> n(%)		
<30	2,173 (8.1)	111 (0.2)
30-44.9	4,576 (17.0)	252 (0.5)
45-59.9	8,190 (30.5)	1,685 (3.4)
60+	10,697 (39.8)	40,029 (81.8)
ACR, median (IQR)	3.93 (1.50-15.00)	1.10 (0.60-2.11)
Deceased: yes, n(%)	563 (2.1)	293 (0.6)

had 1+ encounter between 2019-2021

#### **Microvascular complications**

- neuropathy<sup>7</sup>: ICD9 codes 357.2 or 250.6 or free text "neuropathy" or "neuropathie"
- retinopathy<sup>7</sup>: ICD9 codes 362.0 or free text "retinopathy" or *"retinopathie"* or *"rétinopathie"*
- Nephropathy<sup>7,8</sup>: one ACR >20 mg/mmol or two ACR  $\geq$ 2 mg/mmol within 3 months or two eGFR <60 ml/min/1.73 m<sup>2</sup> separated by between 3 months and 18 months, inclusive

### **Outcome Measures:**

- Prevalence of neuropathy, retinopathy & nephropathy
- sociodemographic & clinical characteristics
  - summary statistics (descriptive analysis)
  - prevalence ratios (logistic regression)

# **Prevalence of Diabetes Complications**

in the Study Population

Given the high prevalence, it is important to prepare for & develop targeted strategies to manage diabetes complications in primary care to reduce the burden on people living with these conditions & to minimize provider burnout

# References

- 1. Phillips LS, Branch Jr WT, Cook CB, et al. Clinical inertia. Annals of internal medicine. 2001;135(9):825-834.
- 2. Zoungas S, Woodward M, Li Q, et al. Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes. Diabetologia. 2014;57:2465-2474.
- 3. Diabetes in Canada: Backgrounder. Ottawa: Diabetes Canada; 2022.
- 4. Zimmerman RS. Diabetes mellitus: management of microvascular and macrovascular complications. J Cleveland Clinic: Centers for Continuing Education. 2016.
- 5. Aronson R, Chu L, Joseph N, Brown R. Prevalence and risk Evaluation of Diabetic complications of the foot among Adults with type 1 and type 2 diabetes in a Large Canadian population (PEDAL study). Canadian Journal of Diabetes. 2021;45(7):588-593.
- 6. Boyd SR, Advani A, Altomare F, Stockl F, Committee CDACPGE. Retinopathy. Canadian journal of diabetes. 2013;37:S137-S141.
- 7. CPCSSN Team, Case Definitions: Canadian Primary Care Sentinel Surveillance Network (CPCSSN), Version 2022-Q4. February 6, 2023.
- 8. Diabetes Canada. Diabetes Canada 2018 clinical practice guidelines for the prevention and management of diabetes in Canada. Diabetes Canada, 2018.

